Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron rilonacept grabs priority status

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Regeneron's BLA for its "Interleukin-1 Trap" agent rilonacept will reach its user fee goal "by the end of November 2007" following FDA's decision to grant priority review status to Regeneron's application, the firm reported Aug. 8. The company announced completion of its rolling BLA for rilonacept for treatment of Cryopyrin-Associated Periodic Syndromes, a spectrum of rare inherited inflammatory conditions, on June 8. Rilonacept was previously granted fast track and orphan drug designations; Regeneron estimates that there are 200 to 500 patients with CAPS in the U.S...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS003653

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel